You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

The material posted on HIV and Hepatitis.com about DDW 2009 is not approved by nor is it a part of DDW 2009.
 HOME Hepatitis C Hepatitis B HIV and AIDS HIV-HCV Coinfection HIV-HBV Coinfection About Us
  HIV and Hepatitis.com Coverage of
 Digestive Disease Week (DDW 2009)
-May 30 - June 4, 2009, Chicago, Illinois
Library of Slides and Posters
Hepatitis B Articles
Hepatitis C Articles
HIV-HCV or HIV-HBV Coinfection Articles


 Google Custom Search
      Library of Slides and Posters

Hepatitis B Slides and Posters
Entecavir (ETV) Therapy in Chronic Hepatitis B Patients Previously Treated with Adefovir (ADV) with Incomplete Response On-Treatment or Relapse Off-Treatment
N Leung and others. DDW 2009.
Long-Term Histological Improvement with Entecavir (ETV) Therapy in Patients with Chronic Hepatitis B (CHB) from Japanese and Worldwide Development Programs
Y Liaw and others. DDW 2009.
Entecavir Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in Nave Patients
D Tenney and others. DDW 2009.
Regression of Fibrosis/Cirrhosis with Long-Term Entecavir Therapy in Chronic Hepatitis B (CHB) Patients with Baseline Bridging Fibrosis or Cirrhosis: Results from Studies ETV-022, -027 and -901
E Schiff and others. DDW 2009.
Association between HBV Replication and Serum ALT Changes is not Dependent on HBV Genotype and Mutants
H Yang and others. DDW 2009.
Risk and Predictors of HCC in People Less than 40 years of Age: Update from the R.E.V.E.A.L.-HBV Study
C Chen and others. DDW 2009.
 

Hepatitis C Slides and Posters
HIV-HCV Coinfected and HCV Monoinfected Patients with Genotype 2-3 Respond Equally Well to 24 Weeks of Pegylated Interferon plus Ribavirin
      Hepatitis C Articles
Many People with Chronic Hepatitis B and C Do Not Receive Appropriate Treatment
6-16-2009
Older Genotype 3 Chronic Hepatitis C Patients Do Not Respond as Well to Interferon-based Therapy
6-16-2009
Asian-American Chronic Hepatitis C Patients Respond Well to Pegylated Interferon plus Ribavirin
6-12-2009
Asian-Americans Are More Likely to Have Unknown Hepatitis C Virus Transmission Risk Factors
6-12-2009
Metabolic Syndrome Is Associated with Increased Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients
6-9-2009
Strategies for Managing Acetaminophen-related Liver Disease and Acute Liver Failure
6-5-2009
Vitamin B12 Levels May Help Predict Response to Interferon-based Therapy for Chronic Hepatitis C
6-5-2009
      Hepatitis B Articles
Predictors of Sustained Treatment Response in HIV-HCV Coinfected Patients Receiving Routine Care
6-16-2009
Many People with Chronic Hepatitis B and C Do Not Receive Appropriate Treatment
6-16-2009
Hepatitis B Prevalence and Susceptibility among Immigrant and U.S.-born Asians and Pacific Islanders
6-12-2009
High HBV DNA Level Is the Strongest Predictor of Elevated ALT
6-9-2009
Should Entecavir (Baraclude) and Tenofovir (Viread) Be First-line Treatment for Chronic Hepatitis B?
6-5-2009
Slides and Posters on Entecavir (Baraclude) and Hepatitis B Liver Disease Progression Presented at DDW 2009
6-5-2009
      HIV-HCV or HIV-HBV Coinfection Articles
Does HIV-HCV Coinfection Increase the Risk of Liver Disease Progression and Worsen Clinical Outcomes?
6-9-2009
HIV-HCV Coinfected and HCV Monoinfected Patients with Genotype 2-3 Respond Equally Well to 24 Weeks of Pegylated Interferon plus Ribavirin
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FDA-approved Combination Therapies for Chronic HCV Infection
Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin
FDA-approved Therapies for Chronic HBV Infection
Baraclude  (entecavir)
Epivir-HBV  (lamivudine; 3TC)
Hepsera   (
adefovir dipivoxil)
Intron A  (interferon alfa-2b)
Pegasys  (peginterferon alfa-2a)
Viread  (tenofovir)
Tyzeka   (telbivudine)
HIV and Hepatitis.com is published by HIV and Hepatitis Treatment Advocates, Inc.